ATIM-39. PHASE 2 OPEN-LABELED STUDY OF ADJUVANT TEMOZOLOMIDE PLUS TUMOR TREATING FIELDS PLUS PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP)

BACKGROUND/OBJECTIVE: Tumor treating Fields (TTFields) plus maintenance temozolomide is an approved standard treatment for newly diagnosed Glioblastoma (GBM). TTFields are alternating electric fields of low intensity and intermediate frequency delivered non-invasively via transducer arrays to tumor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Tran, David, Warren, Sonisha, Allen, Anne, Sampson, Deborah, Chen, Dongjiang, Thomas, Nagheme, Greene, Valerie, Rahman, Maryam, Ghiaseddin, Ashley
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials–Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847508/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.038
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados